Seems that trials are already happening. As a person living with UC, this could be a game changer.

    • ColdCreasent@lemmy.ca
      link
      fedilink
      English
      arrow-up
      30
      ·
      1 year ago

      TLDR would be that any autoimmune disease could see this helping. It “removes/erases” the white blood cells memory of the bodily molecule that we don’t want destroyed from their list of things to destroy.

        • ColdCreasent@lemmy.ca
          link
          fedilink
          English
          arrow-up
          3
          ·
          1 year ago

          With my beginner understanding of the immune response, they could if this is successful. Since allergies are the immune response to an external stimuli instead of an internal stimuli like an autoimmune disorder.

      • Weslee@lemmy.world
        link
        fedilink
        English
        arrow-up
        1
        ·
        1 year ago

        Thank you! That sounds like amazing progress, between this and CRISPR’s progress with cancer, the future looks good for anyone suffering from these

    • SatanicNotMessianic@lemmy.ml
      link
      fedilink
      English
      arrow-up
      4
      ·
      1 year ago

      It’s be a bit premature to do that, if you’re interested as a patient or layperson. It will also be all over the news in five years or so if it works and they bring it to market.

      However, it looks like you could make an alert for the company name (Anokion SA) if you’re interested.

      Those trials are conducted by the pharmaceutical company Anokion SA, which helped fund the new work and which Hubbell cofounded and is a consultant, board member, and equity holder

    • deafboy@lemmy.world
      link
      fedilink
      English
      arrow-up
      28
      ·
      1 year ago

      Not tonight, Pinky…

      phase I safety trials have already been carried out in people with celiac disease, an autoimmune disease that is associated with eating wheat, barley, and rye, and phase I safety trials are underway in multiple sclerosis.

      I know, I know. Safety studies do not judge the effectiveness, but at least they’ve actually moved on from mice to humans this time.

  • Jo@mastodon.social
    link
    fedilink
    arrow-up
    1
    ·
    1 year ago

    @baruchin The technology seems relatively simple and low-risk: tag a molecule with a specific sugar… I wonder if this is something biohackers can manage to do before clinical trials and Big Pharma approval. If so, sign me up! #biohacking